EP2468771A4 - Composition pharmaceutique contenant un anticorps anti-hb-egf comme ingrédient actif - Google Patents

Composition pharmaceutique contenant un anticorps anti-hb-egf comme ingrédient actif

Info

Publication number
EP2468771A4
EP2468771A4 EP10809728.8A EP10809728A EP2468771A4 EP 2468771 A4 EP2468771 A4 EP 2468771A4 EP 10809728 A EP10809728 A EP 10809728A EP 2468771 A4 EP2468771 A4 EP 2468771A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
active ingredient
composition containing
containing anti
egf antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10809728.8A
Other languages
German (de)
English (en)
Other versions
EP2468771A1 (fr
EP2468771A9 (fr
Inventor
Naoki Kimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Forerunner Pharma Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forerunner Pharma Research Co Ltd filed Critical Forerunner Pharma Research Co Ltd
Publication of EP2468771A1 publication Critical patent/EP2468771A1/fr
Publication of EP2468771A4 publication Critical patent/EP2468771A4/fr
Publication of EP2468771A9 publication Critical patent/EP2468771A9/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
EP10809728.8A 2009-08-17 2010-08-17 Composition pharmaceutique contenant un anticorps anti-hb-egf comme ingrédient actif Withdrawn EP2468771A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009003915 2009-08-17
PCT/JP2010/005074 WO2011021381A1 (fr) 2009-08-17 2010-08-17 Composition pharmaceutique contenant un anticorps anti-hb-egf comme ingrédient actif

Publications (3)

Publication Number Publication Date
EP2468771A1 EP2468771A1 (fr) 2012-06-27
EP2468771A4 true EP2468771A4 (fr) 2013-06-05
EP2468771A9 EP2468771A9 (fr) 2014-01-08

Family

ID=43606841

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10809728.8A Withdrawn EP2468771A4 (fr) 2009-08-17 2010-08-17 Composition pharmaceutique contenant un anticorps anti-hb-egf comme ingrédient actif

Country Status (6)

Country Link
US (1) US20120282173A1 (fr)
EP (1) EP2468771A4 (fr)
CN (1) CN102574917A (fr)
AU (1) AU2010285974A1 (fr)
CA (1) CA2771436A1 (fr)
WO (1) WO2011021381A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2589609A1 (fr) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Protéine se liant à un antigène et son utilisation pour l'adressage d'un produit pour le traitement du cancer
FR2988393B1 (fr) 2012-03-20 2014-05-09 Commissariat Energie Atomique Inhibiteur de l'hb-egf derive du domaine r de la toxine diphterique pour le traitement des maladies associees a l'activation de la voie hb-egf/egfr
AU2013305887B2 (en) 2012-08-21 2018-02-22 Saladax Biomedical Inc. Antibodies to risperidone and use thereof
WO2014031645A1 (fr) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Anticorps dirigés contre des haptènes de rispéridone et leur utilisation
AU2013305965B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Antibodies to paliperidone and use thereof
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
HUE049294T2 (hu) 2013-05-15 2020-09-28 Univ Leland Stanford Junior Heparinkötõ epidermális növekedési faktor aktivitás modulálása dobhártya gyógyításához
EP3390449A1 (fr) 2015-12-17 2018-10-24 Janssen Pharmaceutica N.V. Anticorps anti-rispéridone et leur utilisation
CN105505884B (zh) * 2016-01-26 2017-10-03 郑州师范学院 进行抗体表达和组装的重组系统及应用
CN109535252B (zh) * 2018-12-17 2020-04-21 江苏莱森生物科技研究院有限公司 一种抗hb-egf单克隆抗体及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009040134A1 (fr) * 2007-09-26 2009-04-02 U3 Pharma Gmbh Protéines de liaison avec l'antigène du facteur de croissance de type facteur de croissance épidermique se liant à l'héparine

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPS6459878A (en) 1987-08-31 1989-03-07 Matsushita Electric Ind Co Ltd Semiconductor laser protective circuit
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993012227A1 (fr) 1991-12-17 1993-06-24 Genpharm International, Inc. Animaux transgeniques non humains capables de produire des anticorps heterologues
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
CA2131151A1 (fr) 1992-03-24 1994-09-30 Kevin S. Johnson Methodes de production d'elements formant des paires specifiques de liaison
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
CA2161351C (fr) 1993-04-26 2010-12-21 Nils Lonberg Animaux transgeniques, pouvant produire des anticorps heterologues
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
CA2177367A1 (fr) 1993-12-03 1995-06-08 Andrew David Griffiths Proteines et peptides de liaison recombines
AU701342B2 (en) 1994-07-13 1999-01-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
ES2304786T3 (es) 1995-04-27 2008-10-16 Amgen Fremont Inc. Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados.
EP0823941A4 (fr) 1995-04-28 2001-09-19 Abgenix Inc Anticorps humains derives de xeno-souris immunisees
IL129164A (en) 1996-09-26 2007-05-15 Chugai Pharmaceutical Co Ltd An antibody against peptides associated with human parathyroid hormone
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP2275540B1 (fr) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Procédé de contrôle de l'activité de molécule fonctionnelle immunologique
US6503666B1 (en) 2000-07-05 2003-01-07 Numerical Technologies, Inc. Phase shift masking for complex patterns
CA2424602C (fr) 2000-10-06 2012-09-18 Kyowa Hakko Kogyo Co., Ltd. Cellules produisant des compositions d'anticorps
US20030003097A1 (en) 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
EP1514928B1 (fr) 2002-06-05 2013-07-31 Chugai Seiyaku Kabushiki Kaisha Procede de production d'anticorps a l'aide de baculovirus
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
WO2007142277A1 (fr) * 2006-06-06 2007-12-13 Kyowa Hakko Kirin Co., Ltd. Anticorps monoclonal capable de se lier au facteur de croissance de type facteur de croissance épidermique se liant à l'héparine
EP2078731A4 (fr) * 2006-10-20 2012-08-01 Forerunner Pharma Res Co Ltd Composition pharmaceutique comprenant un anticorps anti-hb-egf comme ingrédient actif
CN101589058A (zh) 2006-10-20 2009-11-25 株式会社未来创药研究所 包含抗hb-egf抗体作为活性成分的癌症治疗剂
AU2008332296A1 (en) * 2007-12-05 2009-06-11 Kyowa Hakko Kirin Co., Ltd. Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009040134A1 (fr) * 2007-09-26 2009-04-02 U3 Pharma Gmbh Protéines de liaison avec l'antigène du facteur de croissance de type facteur de croissance épidermique se liant à l'héparine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COLLET T A ET AL: "A BINARY PLASMID SYSTEM FOR SHUFFLING COMBINATORIAL ANTIBODY LIBRARIES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 89, no. 21, 1 November 1992 (1992-11-01), pages 10026 - 10030, XP000322464, ISSN: 0027-8424, DOI: 10.1073/PNAS.89.21.10026 *
See also references of WO2011021381A1 *

Also Published As

Publication number Publication date
EP2468771A1 (fr) 2012-06-27
AU2010285974A1 (en) 2012-03-22
CA2771436A1 (fr) 2011-02-24
WO2011021381A1 (fr) 2011-02-24
CN102574917A (zh) 2012-07-11
EP2468771A9 (fr) 2014-01-08
US20120282173A1 (en) 2012-11-08

Similar Documents

Publication Publication Date Title
HK1246170A1 (zh) 藥物組合物
HK1231408A1 (zh) 藥物組合物
EP2130552A4 (fr) Composition pharmaceutique comportant un anticorps anti-grp 78 en tant qu'ingredient actif
EP2468771A4 (fr) Composition pharmaceutique contenant un anticorps anti-hb-egf comme ingrédient actif
EP2078731A4 (fr) Composition pharmaceutique comprenant un anticorps anti-hb-egf comme ingrédient actif
IL225457A0 (en) Pharmaceutical composition
RS55566B1 (sr) Farmaceutska kompozicija
EP2379077A4 (fr) Composition pharmaceutique
PT2579858E (pt) Composição farmacêutica que contém ivabradina
EP2484697A4 (fr) Anticorps antipodoplanine et composition pharmaceutique contenant un anticorps antipodoplanine
ZA201301920B (en) Pharmaceutical composition
HK1199217A1 (en) Topical pharmaceutical composition including active agents
GB201010453D0 (en) Pharmaceutical composition
PL394605A1 (pl) Trwała złożona kompozycja farmaceutyczna
ZA201103347B (en) Pharmaceutical aerosol composition
ZA201207375B (en) Stabilized pharmaceutical composition
ZA201302012B (en) Low dose pharmaceutical composition
IL221501A (en) Medicinal product containing miramistine
GB201001911D0 (en) Pharmaceutical composition
GB0919650D0 (en) Pharmaceutical composition
HK1182939A1 (en) Stable pharmaceutical composition
GB201019775D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120316

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130506

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101ALI20130426BHEP

Ipc: C12Q 1/02 20060101ALI20130426BHEP

Ipc: A61P 35/00 20060101ALI20130426BHEP

Ipc: C07K 16/22 20060101AFI20130426BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CHUGAI SEIYAKU KABUSHIKI KAISHA

17Q First examination report despatched

Effective date: 20140408

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101ALI20160714BHEP

Ipc: G01N 33/577 20060101ALI20160714BHEP

Ipc: G01N 33/574 20060101ALI20160714BHEP

Ipc: A61P 35/00 20060101ALI20160714BHEP

Ipc: C12Q 1/02 20060101ALI20160714BHEP

Ipc: C07K 16/22 20060101AFI20160714BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160912

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170124